Jenburkt Pharmaceuticals (524731) Q1 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 25/26 earnings summary
12 Aug, 2025Executive summary
Standalone unaudited financial results for the quarter ended 30th June 2025 were approved by the Board on 12th August 2025.
The company operates exclusively in the pharmaceuticals segment.
Financial highlights
Revenue from operations for Q1 FY26 was ₹3,552.68 lakhs, up from ₹3,253.57 lakhs in Q1 FY25.
Total income for the quarter was ₹3,758.39 lakhs, compared to ₹3,394.14 lakhs in the same quarter last year.
Profit before tax for the quarter was ₹1,018.20 lakhs, up from ₹1,006.13 lakhs year-over-year.
Profit after tax stood at ₹853.66 lakhs, compared to ₹741.60 lakhs in Q1 FY25.
Basic and diluted EPS for the quarter was ₹17.66, up from ₹16.80 year-over-year.
Key financial ratios and metrics
Gross margin improved as total expenses increased at a slower rate than revenue year-over-year.
Comprehensive income for the quarter was ₹916.61 lakhs, compared to ₹896.68 lakhs in Q1 FY25.
Latest events from Jenburkt Pharmaceuticals
- H1 revenue advanced, but PAT and EPS declined year over year.524731
Q2 26/27 - Q1 FY27 profit after tax declined to ₹588.56 lakhs, with EPS at ₹13.34.524731Q1 26/27
- Revenue and profit rose, dividend declared, and audit opinion unmodified for FY 2025-26.524731Q4 25/26
- Q3 FY26 saw higher revenue but lower profit after tax and EPS, with added labour cost provisions.524731Q3 25/26
- Revenue and net profit rose year-over-year, with EPS at ₹23.03 and strong cash flow.524731Q2 25/26
- Strong revenue and profit growth reported for Q2 FY25, with higher EPS and cash flow.524731Q2 24/25
- Q1 FY25 saw higher revenue, profit, and EPS, with continued focus on pharmaceuticals.524731Q1 24/25
- Q3 FY25 saw higher revenue, profit, and EPS, with clean auditor review and pharma focus.524731Q3 24/25
- FY25 net profit rose 23% to ₹3,206 lakh; ₹18/share dividend declared.524731Q4 24/25